Interventional , Open-label, Positron Emission Tomography (PET) Study With [18F]-T-401 Investigating MAGL Enzyme Occupancy After Multiple Oral Doses of Lu AG06466

This study is being done to learn about the binding of Lu AG06466 and its major breakdown product (Lu AG06988) in the brain of healthy men having received multiple doses of Lu AG06466. As the binding will result in inhibition of an enzyme in the endocannabinoid system called monoacylglycerol lipase (MAGL), the effects on this system will be evaluated both in the blood and cerebrospinal fluid and compared to the binding in the brain.

Start Date18 Jan 2022

Sponsor / Collaborator

H. Lundbeck A/S

NCT05201092 / CompletedPhase 1

Interventional, Open-Label, Single-Dose Study Investigating the Absorption, Metabolism and Excretion (AME) of Lu AG06466 Following Oral Dosing of 14C-Lu AG06466 to Healthy Men

The purpose of this study is to investigate how the drug Lu AG06466 is absorbed, metabolized, and excreted from the body, for example, what the body does to the drug after swallowing a single dose.

Start Date05 Jan 2022

Sponsor / Collaborator

H. Lundbeck A/S

NCT05177029 / TerminatedPhase 1

Interventional, Randomized, Double-Blind, Sequential-Part, Placebo-Controlled, Single- and Multiple-Dose Study Investigating Safety, Tolerability, and Pharmacokinetic Properties of Lu AG06466 in Healthy Young Japanese and Caucasian Subjects

The main goal of this study is to evaluate the effect of Lu AG06466 on the body and what the body does to Lu AG06466 after single and multiple doses to healthy Japanese and Caucasian participants.

Start Date26 Nov 2021

Sponsor / Collaborator

H. Lundbeck A/S

100 Clinical Results associated with ABX-1431

100 Translational Medicine associated with ABX-1431

100 Patents (Medical) associated with ABX-1431

Literatures (Medical) associated with ABX-1431

01 Dec 2024·Cannabis and cannabinoid research

Acute Effects of Monoacylglycerol Lipase Inhibitor ABX1431 on Neuronal Hyperexcitability, Nociception, Locomotion, and the Endocannabinoid System in HIV-1 Tat Male Mice

Article

Author: Fitting, Sylvia ; Lichtman, Aron H. ; Ignatowska-Jankowska, Bogna M. ; Reissner, Kathryn J. ; Ravula, Havilah P. ; Dodson, Hailey ; Yadav-Samudrala, Barkha J. ; Poklis, Justin L. ; Barmada, Karenna M.

Background: Evidence suggests that monoacylglycerol lipase (MAGL) inhibitors can potentially treat HIV symptoms by increasing the concentration of 2-arachidonoylglycerol (2-AG). We examined a selective MAGL inhibitor ABX1431 in the context of neuroHIV. Methods: To assess the effects of ABX1431, we conducted in vitro and in vivo studies. In vitro calcium imaging on frontal cortex neuronal cultures was performed to evaluate the role of ABX1431 (10, 30, 100 nM) on transactivator of transcription (Tat)-induced neuronal hyperexcitability. Following in vitro experiments, in vivo experiments were performed using Tat transgenic male mice. Mice were treated with 4 mg/kg ABX1431 and assessed for antinociception using tail-flick and hot plate assays followed by locomotor activity. After the behavioral experiments, their brains were harvested to quantify endocannabinoids (eCB) and related lipids through mass spectrometry, and cannabinoid type-1 and -2 receptors (CB₁R and CB₂R) were quantified through western blot. Results: In vitro studies revealed that adding Tat directly to the neuronal cultures significantly increased intracellular calcium concentration, which ABX1431 completely reversed at all concentrations. Preincubating the cultures with CB₁R and CB₂R antagonists showed that ABX1431 exhibited its effects partially through CB₁R. In vivo studies demonstrated that acute ABX1431 increased overall total distance traveled and speed of mice regardless of their genotype. Mass spectrometry and western blot analyses revealed differential effects on the eCB system based on Tat expression. The 2-AG levels were significantly upregulated following ABX1431 treatment in the striatum and spinal cord. Arachidonic acid (AA) was also upregulated in the striatum of vehicle-treated Tat(+) mice. No changes were noted in CB₁R expression levels; however, CB₂R levels were increased in ABX1431-treated Tat(-) mice only. Conclusion: Findings indicate that ABX1431 has potential neuroprotective effects in vitro partially mediated through CB₁R. Acute treatment of ABX1431 in vivo shows antinociceptive effects, and seems to alter locomotor activity, with upregulating 2-AG levels in the striatum and spinal cord.

12 Oct 2024·Journal of biomolecular structure & dynamics

Supervised screening of Tecovirimat-like compounds as potential inhibitors for the monkeypox virus E8L protein

Article

Author: Kaushik, Aman Chandra ; Nawab, Sadia ; Jia, Guihua ; Wei, Dong-Qing ; Mehmood, Aamir

Monkeypox virus (MPXV) is a budding public health threat worldwide, and there lacks a personalized drug availability to treat MPXV infections. Tecovirimat, an antiviral drug against pox viruses, is recently confirmed to be effective against the MPXV in vitro using nanomolar concentrations. Therefore, the current study considers Tecovirimat as a reference compound for a machine learning-based guided screening to scan bioactive compounds from the DrugBank with similar chemical features or moieties as the Tecovirimat to inhibit the MPXV E8L surface binding protein. We used AlphaFold2 to model the E8L's 3D structure, followed by the conformational activity investigation of shortlisted drugs through computational structural biology approaches, including molecular docking and molecular dynamics simulations. As a result, we have shortlisted five drugs named ABX-1431, Alflutinib, Avacopan, Caspitant, and Darapalib that effectively engage the MPXV surface binding protein. Furthermore, the affinity of the proposed drugs is relatively higher than the Tecovirimat by having higher docking scores, establishing more hydrogen and hydrophobic bonds, engaging key residues in the target's structure, and exhibiting stable molecular dynamics.Communicated by Ramaswamy H. Sarma.

01 Aug 2024·Cannabis and cannabinoid research

The Monoacylglycerol Lipase Inhibitor ABX-1431 Does Not Improve Alcoholic Liver Disease.

Article

Author: Maitra, Rangan ; Laudermilk, Lucas T ; Amato, George S ; Lucitti, Jennifer L

Introduction: Excessive alcohol consumption can result in alcoholic liver disease (ALD). There is no FDA-approved drug to specifically treat ALD and current management approaches have limited efficacy. Past studies indicate that monoacylglycerol lipase (MAGL) inhibition can have a positive impact on nonalcoholic fatty liver disease. However, the effect of MAGL inhibition in ALD has not been reported. Materials and Methods: We tested the highly selective and clinically evaluated MAGL inhibitor ABX-1431 in the Lieber-DeCarli liquid alcohol diet-induced model of ALD in C57BL/6 mice. Results: ABX-1431 failed to reduce ALD-associated steatosis and elevated levels of liver enzymes associated with hepatic injury. Furthermore, survival rate declined with increasing doses of ABX-1431 when compared with mice administered vehicle only. Conclusion: These data suggest that MAGL inhibition does not improve ALD and is unlikely to be a good strategy for this condition.

News (Medical) associated with ABX-1431

11 Apr 2023

·www.prnewswire.com

DelveInsight Evaluates a Robust Epilepsy Pipeline as 70+ Influential Pharma Players to Set Foot in the Domain

The prevalence of Epilepsy has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Epilepsy and the growing research and development activities to develop novel therapies to treat Epilepsy to drive the market. The companies developing the potential therapies in the last stage of development include Xenon Pharmaceuticals, Engage Therapeutics, Janssen Biotech, and several others LAS VEGAS, April 11, 2023 /PRNewswire/ -- DelveInsight's ' Epilepsy Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline epilepsy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the epilepsy pipeline domain. Key Takeaways from the Epilepsy Pipeline Report DelveInsight's epilepsy pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for epilepsy treatment. Key epilepsy companies such as Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics, Equilibre Biopharmaceuticals, ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics, Cerebral Therapeutics, Engrail Therapeutics, and others are evaluating new epilepsy drugs to improve the treatment landscape. Promising epilepsy pipeline therapies in various stages of development include Alprazolam, XEN1101, XEN-496, XEN 901, GWP42006, EQU-001, TAK-935, Lu AG06466, OPC-214870, CG 01, EQU-001, ES-481, SPN-817, MGCND00EP1, NBI 827104, ENX-101, Cenobamate, SKL-24741, LP-352, JNJ-40411813, EQU-001, CVL-865, NRTX 1001, PRAX 628, Padsevonil, RLS103, NPT 2042, AVCN-319302, PRAX-020, AMZ002, OV 350, IAMA-6, CT-010, ENX-101, and others. In March 2023, IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced that preclinical data supporting its IAMA-6 program in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27 in Boston, Massachusetts. In February 2023, Addex Therapeutics announced that enrollment into Part 1 of Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy had been completed. ADX71149 is a selective metabotropic glutamate type 2 (mGlu2) receptor-positive allosteric modulator (PAM). Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, is conducting the trial. In January 2023, Equilibre Biopharmaceuticals Corp., reported positive topline results from the Phase 2 clinical trial evaluating the clinical safety, tolerability, and preliminary efficacy of EQU-001 – a novel anti-inflammatory anti-seizure medication - administered as once-daily oral adjunctive therapy for focal seizures in adults with epilepsy. The results of the EQU-001 study are encouraging because they demonstrate impressive tolerability and encouraging efficacy for adult patients with focal epilepsy, especially for those with seizures that are difficult to treat. In January 2023, Signant Health, introduced a novel electronic diary (eDiary) data capture solution designed to simplify the experience for patients and research sites participating in epilepsy trials while ensuring robust outcome assessment data to support trial endpoints. Developed in collaboration with The Epilepsy Study Consortium (TESC), the new patient-reported outcome measure offers clinical research sponsors and organizations a standardized solution to capture common seizure data elements with high-quality data. In June 2022, CODA Biotherapeutics, Inc. announced that preclinical data from the Company's focal epilepsy program demonstrated that treatment with the Company's lead-engineered receptor and small molecule activator drug significantly reduced focal seizure frequency in vivo. Results showed that the rapid reduction in seizures is consistent with the pharmacokinetics of the activator drug in mouse models. Data also demonstrated that the expression of CODA's lead receptor is highly correlated with a reduction in seizure frequency. In September 2022, Avicanna Inc. was pleased to announce that it has expanded its research collaboration in the field of Epilepsy with a new collaboration with the University of Toronto and Dr. Mac Burnham's research team to explore the efficacy of Avicanna's proprietary formulations in pre-clinical models for Epilepsy. The research collaboration led by Dr. Mac Burnham's team will explore the efficacy of Avicanna's drug candidates, including AVCN319302, in animal models for Epilepsy. In December 2022, Praxis Precision Medicines, Inc. and UCB announced a strategic collaboration, based upon Praxis' PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the collaboration, UCB retains an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate. In January 2022, Ovid Therapeutics Inc. announced the company has entered into an exclusive license agreement with AstraZeneca for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. The company seeks to optimize and accelerate the development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions. In August 2021, Marinus Pharmaceuticals, Inc. announced that it has entered into an agreement with Orion Corporation whereby Orion received exclusive rights to commercialize the oral and intravenous (IV) dose formulations of ganaxolone in the European Economic Area, United Kingdom, and Switzerland for CDKL5 deficiency disorder (CDD), tuberous sclerosis complex (TSC) and refractory status epilepticus (RSE). Request a sample and discover the recent advances in epilepsy drug treatment @ Epilepsy Pipeline Report The epilepsy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage epilepsy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the epilepsy clinical trial landscape. Epilepsy Overview Epilepsy is a chronic condition characterized by unprovoked, recurrent seizures. A seizure is an uncontrollable surge of electrical activity in the brain. Seizures are classified into two types. Seizures that affect the entire brain are known as generalized seizures. Focal seizures, also known as partial seizures, affect only one part of the brain. A mild seizure can be difficult to detect. It can last a few seconds, and you are unaware of it. Stronger seizures, lasting from a few seconds to several minutes, can cause spasms and uncontrollable muscle twitches. Epilepsy symptoms vary according to the area of the brain where seizure activity occurs and the type of seizure. Epilepsy symptoms may include: stiff muscles, Become stiff and falling backward, muscles relaxing and going floppy, confusion, breathing becomes difficult, unconscious, visual disturbances/hallucinations, uncontrollable jerking and shaking, called a "fit," losing awareness and staring blankly into space, strange sensations, such as a "rising" feeling in the tummy, unusual smells or tastes, and a tingling feeling in your arms or legs and collapsing. Epilepsy treatment can help most people with epilepsy have fewer seizures or completely stop having seizures. Find out more about drugs for epilepsy @ New Epilepsy Drugs A snapshot of the Epilepsy Pipeline Drugs mentioned in the report: Learn more about the emerging epilepsy pipeline therapies @ Epilepsy Clinical Trials Epilepsy Therapeutics Assessment The epilepsy pipeline report proffers an integral view of epilepsy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Epilepsy Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: KCNQ potassium channel agonists, Monoacylglycerol lipase inhibitors, Cholesterol 24-hydroxylase inhibitors, NMDA receptor modulators, AMPA receptor antagonists, GABA A receptor agonists, Cannabinoid receptor modulators Key Epilepsy Companies: Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics, Equilibre Biopharmaceuticals, ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics, Cerebral Therapeutics, Engrail Therapeutics, and others. Key Epilepsy Pipeline Therapies: Alprazolam, XEN1101, XEN-496, XEN 901, GWP42006, EQU-001, TAK-935, Lu AG06466, OPC-214870, CG 01, EQU-001, ES-481, SPN-817, MGCND00EP1, NBI 827104, ENX-101, Cenobamate, SKL-24741, LP-352, JNJ-40411813, EQU-001, CVL-865, NRTX 1001, PRAX 628, Padsevonil, RLS103, NPT 2042, AVCN-319302, PRAX-020, AMZ002, OV 350, IAMA-6,CT-010, ENX-101, and others. Dive deep into rich insights for new drugs for epilepsy treatment; visit @ Epilepsy Medications Table of Contents For further information on the epilepsy pipeline therapeutics, reach out @ Epilepsy Drug Treatment Related Reports Epilepsy Market Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies including Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, among others. Epilepsy Epidemiology Forecast Epilepsy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epilepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Refractory Epilepsy Pipeline Refractory Epilepsy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory epilepsy companies, including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others. Partial Epilepsy Pipeline Partial Epilepsy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key partial epilepsy companies, including GW Pharmaceuticals, Equilibre Biopharmaceuticals, among others. Refractory Epilepsy Market Refractory Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory epilepsy companies including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others. Partial Epilepsy Market Partial Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key partial epilepsy companies, including GW Pharmaceuticals, Equilibre Biopharmaceuticals, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Telepyschiatry Market Digital Therapeutics for Mental Health Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Phase 2Clinical ResultLicense out/in

05 Aug 2021

·www.globenewswire.com

A Robust Neuromyelitis Optica Spectrum Disorder Pipeline Domain Witnesses Several Novel and Promising Therapies in Different Stages of Clinical Development Expected to Enter the Market by the Next Dec

Los Angeles, USA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A Robust Neuromyelitis Optica Spectrum Disorder Pipeline Domain Witnesses Several Novel and Promising Therapies in Different Stages of Clinical Development Expected to Enter the Market by the Next Decade DelveInsight’s analysis demonstrates a robust Neuromyelitis Optica Spectrum Disorder Pipeline with 15+ active players in the domain working on 15+ pipeline therapies. DelveInsight’s ‘Neuromyelitis Optica Spectrum Disorder Pipeline Insights’ report presents an exhaustive coverage of the available therapies, Neuromyelitis Optica Spectrum Disorder emerging therapies in different phases of clinical development, key companies working in the Neuromyelitis Optica Spectrum Disorder pipeline domain, and future potential of the space. Some of the notable pointers extracted from the Neuromyelitis Optica Spectrum Disorder Pipeline report: Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Neuromyelitis Optica Spectrum Disorder Emerging Therapies and Forecast The Neuromyelitis Optica Spectrum Disorder Pipeline reports lays down a comprehensive structure of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Neuromyelitis Optica Spectrum Disorder domain. Neuromyelitis Optica Spectrum Disorder Overview Neuromyelitis Optica Spectrum Disorder (NMOSD), also referred to as Devic disease, is a chronic condition that causes inflammation of the optic nerve and spinal cord thereby affecting the brain and spinal cord. The condition is an autoimmune disorder, however, the exact pathophysiology and cause of the autoimmunity remain unclear. Discover more about the disease, treatments, and pipeline therapies @ NMOSD Pipeline Assessment Neuromyelitis Optica Spectrum Disorder Pipeline Drugs Request for Sample to know more @ Neuromyelitis Optica Spectrum Disorder Pipeline Analysis, Key Companies, and Futuristic Trends Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment The Neuromyelitis Optica Spectrum Disorder Pipeline report presents a holistic picture of the Neuromyelitis Optica Spectrum Disorder emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets For rich insights into merging therapies and assessment, visit NMOSD Pipeline Emerging Novel Therapies Scope of the Neuromyelitis Optica Spectrum Disorder Pipeline Report Coverage: GlobalKey Players: Alexion Pharmaceuticals, RemeGen, Reistone Biopharma, Chord Therapeutics, Nihon Pharmaceuticals, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, Boston Pharmaceuticals, and TG Therapeutics among others.Key Neuromyelitis Optica Spectrum Disorder Pipeline Therapies: Ravulizumab, Telitacicept, SHR1459, CRD1, HBM9161, BAT4406F, ABX-1431, BN201, ARN-6039, and Ublituximab among others.Discover more about the scope of the report @ Neuromyelitis Optica Spectrum Disorder Emerging Therapies, Treatments, and Ongoing Clinical Trials Table of Contents Learn more about the report offerings @ Neuromyelitis Optica Spectrum Disorder Pipeline Therapies and Emerging Trends Audit the market before venturing with DelveInsight’s Due Diligence Services Related Reports Neuromyelitis Optica Spectrum Disorder MarketDelveInsight's "Neuromyelitis Optica Spectrum Disorder (Neuromyelitis Optica Spectrum Disorder) Market Insights, Epidemiology and Market Forecast-2028" report. Pompe Disease Market Insight Epidemiology And Market ForecastDelveInsight's "Pompe Disease Market Insights, Epidemiology and Market Forecast-2028" report. Spinal Muscular Atrophy Sma Market Insight Epidemiology And Market ForecastDelveInsight's 'Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2028' report. Spinocerebellar Ataxias Market Insights Epidemiology And Market ForecastDelveInsight's 'Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028’ report. Acute Ischemic Stroke Market InsightsDelveInsight’s ‘Acute Ischemic Stroke (AIS) - Market Insights, Competitive Landscape and Market Forecast–2026’ report. Adult Intraventricular Hemorrhage MarketDelveInsight’s ‘Adult Intraventricular Haemorrhage Market Insights, Competitive Landscape and Market Forecast-2026’ report. Carotid Stenotic Scan Devices MarketDelveInsight’s ‘Carotid Stenotic Scan Devices Market Insights, Competitive Landscape and Market Forecast-2026’ report. Browse through our posts Dynamics Of Schizophrenia MarketAlzheimer’s Disease Market LandscapeAdvancements in Neuromodulation in the Neurological Disorders MarketDeep Brain Stimulation Devices and Changing Market Landscape About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

100 Deals associated with ABX-1431

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16036

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tourette Syndrome	Phase 2	DE	Abide Therapeutics, Inc.	15 Oct 2018
Tourette Syndrome	Phase 2	PL	Abide Therapeutics, Inc.	15 Oct 2018
Tourette Syndrome	Phase 2	ES	Abide Therapeutics, Inc.	15 Oct 2018
Epilepsies, Partial	Phase 1	US	H. Lundbeck A/S	29 Sep 2021
Muscle Spasticity	Phase 1	US	H. Lundbeck A/S	27 Sep 2021
Muscle Spasticity	Phase 1	DE	H. Lundbeck A/S	27 Sep 2021
Fibromyalgia	Phase 1	US	H. Lundbeck A/S	24 Jun 2021
Neuroinflammation	Phase 1	US	H. Lundbeck A/S	24 Jun 2021
Stress Disorders, Post-Traumatic	Phase 1	US	H. Lundbeck A/S	30 Sep 2020
Diabetic peripheral neuropathy	Phase 1	MD	Abide Therapeutics, Inc.	02 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03625453 (PipelineReview) Manual	Phase 2	Tourette Syndrome	48	Lu AG06466	cniatirpaa(fbyysulsbf) = fatigue, disturbance in attention, nasopharyngitis and paresthesia. amtfljmcnz (qvtwhuuvrr )	Negative	30 Mar 2020
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis